| Total (N = 353) | axSpA (n = 229) | PsA (N = 118)) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases (n = 210) | Controls (n = 143) | p | Cases (n = 132) | Controls (n = 97) | p | Cases (n = 75) | Controls (n = 43) | p | |||||||
n | % | N | % | n | % | n | % | n | % | n | % | ||||
Male | 112 | 57.4 | 83 | 42.6 | 0.382 | 77 | 53.5 | 67 | 46.5 | 0.096 | 35 | 70.0 | 15 | 30,0 | 0.213 |
Profession | |||||||||||||||
 Health care, security, and education | 46 | 70.8 | 19 | 29.2 | 0.038 | 33 | 67.3 | 16 | 32.7 | 0.114 | 12 | 80.0 | 3 | 20.0 | 0.250(a) |
Work status—active | 117 | 63.2 | 68 | 36.8 | 0.109 | 80 | 61.1 | 51 | 38.9 | 0.200 | 37 | 71.2 | 15 | 28.8 | 0.113 |
No social distancing | 81 | 58.7 | 57 | 41.3 | 0.835 | 51 | 56.7 | 39 | 43.3 | 0.846 | 30 | 63.8 | 17 | 36.2 | 0.960 |
HLA-B27 positivity# | 69 | 57.5 | 51 | 42.5 | 0.704 | 64 | 57.1 | 48 | 42.0 | 0.514 | 5 | 62.5 | 3 | 37.5 | 0.677(a) |
Comorbidities, N (%) | |||||||||||||||
 Hypertension | 81 | 63.8 | 46 | 36.2 | 0.218 | 44 | 62.0 | 27 | 38.0 | 0.374 | 35 | 64.8 | 19 | 35.2 | 0.795 |
 Diabetes mellitus | 32 | 62.7 | 19 | 37.3 | 0.609 | 12 | 52.2 | 11 | 47.8 | 0.576 | 20 | 71.4 | 8 | 28.6 | 0.322 |
 Obesity | 31 | 62.0 | 19 | 38.0 | 0.696 | 16 | 64.0 | 9 | 36.0 | 0.495 | 15 | 62.5 | 9 | 37.5 | 0.904 |
 Cardiopathy | 16 | 72.7 | 6 | 27.3 | 0.192 | 9 | 75.0 | 3 | 25.0 | 0.246(a) | 7 | 70.0 | 3 | 30.0 | 0.745(a) |
 Lung disease | 12 | 92.3 | 1 | 7.7 | 0.018 | 9 | 90.0 | 1 | 10.0 | 0.047(a) | 3 | 100.0 | 0 | 0 | – |
 Kidney disease | 4 | 57.1 | 3 | 42.9 | 1.000 | 1 | 25.0 | 3 | 75.0 | 0.314(a) | 3 | 100.0 | 0 | 0 | – |
 Others | 57 | 59.4 | 39 | 40.6 | 0.979 | 33 | 58.9 | 23 | 41.1 | 0.823 | 22 | 57.9 | 16 | 42.1 | 0.378 |
Number of comorbidities | |||||||||||||||
 None | 70 | 52.2 | 64 | 47.8 | 0.030 | 50 | 50.5 | 49 | 49.5 | 0.056 | 20 | 60.6 | 13 | 39.4 | 0.678 |
 One or more | 67 | 31.9 | 31 | 21.7 | 0.035 | 43 | 32.6 | 20 | 20.6 | 0.045 | 22 | 29.3 | 10 | 23.3 | 0.475 |
Current smoking | 12 | 54.2 | 11 | 45.8 | 0.570 | 7 | 58.3 | 5 | 41.7 | 0.975 | 6 | 50.0 | 6 | 50.0 | 0.303 |
Oral corticosteroids | 14 | 82.4 | 3 | 17.6 | 0.074 | 6 | 75.0 | 2 | 25.0 | 0.472(a) | 8 | 100.0 | 0 | 0 | 0.027(a) |
DMARDs | |||||||||||||||
 TNF inhibitors | 139 | 59.4 | 95 | 40.6 | 0.962 | 100 | 58.5 | 70 | 41.2 | 0.539 | 38 | 63.8 | 21 | 36.2 | 0.959 |
 IL17 inhibitors | 28 | 56.0 | 22 | 44.0 | 0.587 | 11 | 47.8 | 12 | 52.2 | 0.315 | 17 | 63.0 | 10 | 37.0 | 0.942 |
 IL12/23 inhibitors | 1 | 33.3 | 2 | 66.7 | 0.568 | 0 | 0 | 0 | 0 | - | 1 | 33.3 | 2 | 66.7 | 0.553(a) |
 Leflunomide | 11 | 68.6 | 5 | 31.3 | 0.440 | 1 | 50.0 | 1 | 50.0 | 1.000 | 10 | 71.4 | 4 | 28.6 | 0.571(a) |
 Methotrexate | 43 | 53.1 | 38 | 46.9 | 0.181 | 17 | 53.1 | 15 | 46.9 | 0.577 | 26 | 54.2 | 22 | 45.8 | 0.079 |
 Sulfasalazine | 19 | 65.5 | 10 | 34.5 | 0.490 | 17 | 63.0 | 10 | 37.0 | 0.551 | 1 | 100.0 | 0 | 0 | - |
Age in years, mean (SD)(b) | 48.4 (12.9) | Â | 48.4 (11.6) | Â | 0.964 | 45.8 (12.7) | Â | 45.4 (10.7) | Â | 0.801 | 52.5 (12.4) | Â | 55.0 (11.3) | Â | 0.270 |
Ab. circumference (cm), mean (SD) (b) | 93.4 (15.3) | Â | 91.2 (15.2) | Â | 0.018 | 93.7 (14.8) | Â | 95.6 (15/3) | Â | 0.490 | 98.6 (13.0) | Â | 98.7 (6.0) | Â | 0.962 |
Weight (kg), mean (SD) (b) | 74.1 (6.5) | Â | 71.8 (6.1) | Â | 0.006 | 79.3 (16.8) | Â | 80.7 (16.7) | Â | 0.591 | 79.9 (4.1) | Â | 78.3 (16.7) | Â | 0.616 |
BMI (kg/m2), mean (SD) (b) | 28.7 (14.8) | Â | 28.0(9.4) | Â | 0.295 | 27.8 (5.1) | Â | 30.2 (18.3) | Â | 0.256 | 29.6 (5.3) | Â | 31.5 (18.2) | Â | 0.527 |
SBP (mmHg), mean (SD) (b) | 124.8 (17.5) | Â | 125.4 (5.2) | Â | 0.546 | 125.1 (14.7) | Â | 130.0 (18.5) | Â | 0.062 | 129.5 (16.1) | Â | 131.3 (17.3) | Â | 0.623 |
DBP (mmHg), mean (SD)(b) | 79.4 (11.0) | Â | 79.6 (11.6) | Â | 0.757 | 80.0 (11.1) | Â | 81.2 (11.6) | Â | 0.482 | 82.5 (10.5) | Â | 81.8 (11.4) | Â | 0.755 |
Disease duration (years), mean (SD)(b) | 10.4(9,9) | Â | 11.4 (9,1) | Â | 0.325 | 9.9 (10.1) | Â | 11.2 (8.8) | Â | 0.322 | 11.1 (9,6) | Â | 11.8 (9,9) | Â | 0.716 |